Search

Your search keyword '"Becette, Véronique"' showing total 130 results
Start Over Author "Becette, Véronique"
130 results on '"Becette, Véronique"'

1. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway

Author

Licaj, Monika, Mhaidly, Rana, Kieffer, Yann, Croizer, Hugo, Bonneau, Claire, Meng, Arnaud, Djerroudi, Lounes, Mujangi-Ebeka, Kevin, Hocine, Hocine R., Bourachot, Brigitte, Magagna, Ilaria, Leclere, Renaud, Guyonnet, Lea, Bohec, Mylene, Guérin, Coralie, Baulande, Sylvain, Kamal, Maud, Le Tourneau, Christophe, Lecuru, Fabrice, Becette, Véronique, Rouzier, Roman, Vincent-Salomon, Anne, Gentric, Geraldine, and Mechta-Grigoriou, Fatima

Published
2024
Full Text
View/download PDF

2. Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France

Author

Franchet, Camille, Djerroudi, Lounes, Maran-Gonzalez, Aurélie, Abramovici, Olivia, Antoine, Martine, Becette, Véronique, Berghian, Anca, Blanc-Fournier, Cécile, Brabencova, Eva, Charafe-Jauffret, Emmanuelle, Chenard, Marie-Pierre, Dauplat, Marie-Mélanie, Delrée, Paul, Duprez-Paumier, Raphaëlle, Fleury, Clémence, Ghnassia, Jean-Pierre, Haudebourg, Juliette, Leroux, Agnès, MacGrogan, Gaëtan, Mathieu, Marie-Christine, Michenet, Patrick, Penault-Llorca, Frédérique, Poulet, Bruno, Robin, Yves Marie, Roger, Pascal, Russ, Elisabeth, Tixier, Lucie, Treilleux, Isabelle, Valent, Alexander, Verriele, Véronique, Vincent-Salomon, Anne, Arnould, Laurent, and Lacroix-Triki, Magali

Published
2021
Full Text
View/download PDF

3. Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein

Author

Maran-Gonzalez, Aurélie, Franchet, Camille, Duprez-Paumier, Raphaëlle, Antoine, Martine, Barlier, Catherine, Becette, Véronique, Berghian, Anca, Blanc-Fournier, Cécile, Brabencova, Eva, Charafe-Jauffret, Emmanuelle, Chenard, Marie-Pierre, Dauplat, Marie-Mélanie, Delrée, Paul, Fleury, Clémence, Garbar, Christian, Ghnassia, Jean-Pierre, Haudebourg, Juliette, MacGrogan, Gaëtan, Mathieu, Marie-Christine, Michenet, Patrick, Penault-Llorca, Frédérique, Poulet, Bruno, Robin, Yves, Roger, Pascal, Russ, Elisabeth, Treilleux, Isabelle, Valent, Alexander, Verriele, Véronique, Vincent-Salomon, Anne, Arnould, Laurent, and Lacroix-Triki, Magali

Published
2019
Full Text
View/download PDF

4. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

Author

Lerebours, Florence, Pulido, Marina, Fourme, Emmanuelle, Debled, Marc, Becette, Véronique, Bonnefoi, Hervé, Rivera, Sofia, MacGrogan, Gaetan, Mouret-Reynier, Marie-Ange, de Lara, Christine Tunon, Pierga, Jean-Yves, Breton-Callu, Christel, Venat-Bouvet, Laurence, Mathoulin-Pélissier, Simone, de la Motte rouge, Thibault, Dalenc, Florence, Sigal, Brigitte, Bachelot, Thomas, Lemonnier, Jérôme, and Quenel-Tueux, Nathalie

Published
2020
Full Text
View/download PDF

5. Mosaic BRCA1 promoter methylation contribution in hereditary breast/ovarian cancer pedigrees.

Author

Schwartz, Mathias, Ibadioune, Sabrina, Chansavang, Albain, Vacher, Sophie, Caputo, Sandrine M., Delhomelle, Hélène, Wong, Jennifer, Abidallah, Khadija, Moncoutier, Virginie, Becette, Véronique, Popova, Tatiana, Suybeng, Voreak, De Pauw, Antoine, Stern, Marc-Henri, Colas, Chrystelle, Mouret-Fourme, Emmanuelle, Stoppa-Lyonnet, Dominique, Golmard, Lisa, Bieche, Ivan, and Masliah-Planchon, Julien

Abstract

Purpose Mosaic BRCA1 promoter methylation (BRCA1meth) increases the risk of early-onset breast cancer, triple-negative breast cancer and ovarian cancer. As mosaic BRCA1meth are believed to occur de novo, their role in family breast/ovarian cancer has not been assessed. Patients Blood-derived DNA from 20 unrelated affected cases from families with aggregation of breast/ovarian cancer, but with no germline pathogenic variants in BRCA1/2, PALB2 or RAD51C/D, were screened by methylation-sensitive high-resolution melting. CpG analysis was performed by pyrosequencing on blood and buccal swab. Two probands carried a pathogenic variant in a moderate-penetrance gene (ATM and BARD1), and 8 of 18 others (44%) carried BRCA1meth (vs none of the 20 age-matched controls). Involvement of BRCA1 in tumourigenesis in methylated probands was demonstrated in most tested cases by detection of a loss of heterozygosity and a homologous recombination deficiency signature. Among the eight methylated probands, two had relatives with breast cancer with detectable BRCA1meth in blood, including one with high methylation levels in two non-tumour tissues. Conclusions The high prevalence of mosaic BRCA1meth in patients with breast/ovarian cancer with affected relatives, as well as this first description of a family aggregation of mosaic BRCA1meth, shows how this de novo event can contribute to hereditary breast/ovarian cancer pedigrees. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Mosaic BRCA1promoter methylation contribution in hereditary breast/ovarian cancer pedigrees

Author

Schwartz, Mathias, Ibadioune, Sabrina, Chansavang, Albain, Vacher, Sophie, Caputo, Sandrine M, Delhomelle, Hélène, Wong, Jennifer, Abidallah, Khadija, Moncoutier, Virginie, Becette, Véronique, Popova, Tatiana, Suybeng, Voreak, De Pauw, Antoine, Stern, Marc-Henri, Colas, Chrystelle, Mouret-Fourme, Emmanuelle, Stoppa-Lyonnet, Dominique, Golmard, Lisa, Bieche, Ivan, and Masliah-Planchon, Julien

Abstract

PurposeMosaic BRCA1promoter methylation (BRCA1meth) increases the risk of early-onset breast cancer, triple-negative breast cancer and ovarian cancer. As mosaic BRCA1meth are believed to occur de novo, their role in family breast/ovarian cancer has not been assessed.PatientsBlood-derived DNA from 20 unrelated affected cases from families with aggregation of breast/ovarian cancer, but with no germline pathogenic variants in BRCA1/2, PALB2or RAD51C/D, were screened by methylation-sensitive high-resolution melting. CpG analysis was performed by pyrosequencing on blood and buccal swab. Two probands carried a pathogenic variant in a moderate-penetrance gene (ATMand BARD1), and 8 of 18 others (44%) carried BRCA1meth (vs none of the 20 age-matched controls). Involvement of BRCA1in tumourigenesis in methylated probands was demonstrated in most tested cases by detection of a loss of heterozygosity and a homologous recombination deficiency signature. Among the eight methylated probands, two had relatives with breast cancer with detectable BRCA1meth in blood, including one with high methylation levels in two non-tumour tissues.ConclusionsThe high prevalence of mosaic BRCA1meth in patients with breast/ovarian cancer with affected relatives, as well as this first description of a family aggregation of mosaic BRCA1meth, shows how this de novo event can contribute to hereditary breast/ovarian cancer pedigrees.

Published
2024
Full Text
View/download PDF

7. Adaptive nanopore sequencing to determine pathogenicity of BRCA1 exonic duplication.

Author

Filser, Mathilde, Schwartz, Mathias, Merchadou, Kevin, Hamza, Abderaouf, Villy, Marie-Charlotte, Decees, Antoine, Frouin, Eléonore, Girard, Elodie, Caputo, Sandrine M, Renault, Victor, Becette, Véronique, Golmard, Lisa, Servant, Nicolas, Stoppa-Lyonnet, Dominique, Delattre, Olivier, Colas, Chrystelle, and Masliah-Planchon, Julien

Abstract

BRCA1 and BRCA2 are tumour suppressor genes that have been characterised as predisposition genes for the development of hereditary breast and ovarian cancers among other malignancies. The molecular diagnosis of this predisposition syndrome is based on the detection of inactivating variants of any type in those genes. But in the case of structural variants, functional consequences can be difficult to assess using standard molecular methods, as the precise resolution of their sequence is often impossible with short-read next generation sequencing techniques. It has been recently demonstrated that Oxford Nanopore long read sequencing technology can accurately and rapidly provide genetic diagnoses of Mendelian diseases, including those linked to pathogenic structural variants. Here, we report the accurate resolution of a germline duplication event of exons 18–20 of BRCA1 using Nanopore sequencing with adaptive sampling target enrichment. This allowed us to classify this variant as pathogenic within a short timeframe of 10 days. This study provides a proof-of-concept that nanopore adaptive sampling is a highly efficient technique for the investigation of structural variants of tumour suppressor genes in a clinical context. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Author

Liang, Xu, Briaux, Adrien, Becette, Véronique, Benoist, Camille, Boulai, Anais, Chemlali, Walid, Schnitzler, Anne, Baulande, Sylvain, Rivera, Sofia, Mouret-Reynier, Marie-Ange, Bouvet, Laurence Venat, De La Motte Rouge, Thibaut, Lemonnier, Jérôme, Lerebours, Florence, and Callens, Céline

Published
2018
Full Text
View/download PDF

10. APCgermline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?

Author

Vibert, Roseline, primary, Le Gall, Jessica, additional, Buecher, Bruno, additional, Mouret-Fourme, Emmanuelle, additional, Bataillon, Guillaume, additional, Becette, Véronique, additional, Trabelsi-Grati, Olfa, additional, Moncoutier, Virginie, additional, Dehainault, Catherine, additional, Carriere, Jennifer, additional, Schwartz, Mathias, additional, Suybeng, Voreak, additional, Bieche, Ivan, additional, Colas, Chrystelle, additional, Vincent-Salomon, Anne, additional, Stoppa-Lyonnet, Dominique, additional, and Golmard, Lisa, additional

Published
2022
Full Text
View/download PDF

11. Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France

Author

Penault-Llorca, Frédérique, Vincent-Salomon, Anne, MacGrogan, Gaëtan, Roger, Pascal, Treilleux, Isabelle, Valent, Alexander, Mathieu, Marie-Christine, Antoine, Martine, Becette, Véronique, Bor, Catherine, Brabencova, Eva, Charafe-Jauffret, Emmanuelle, Chenard, Marie-Pierre, Dauplat, Marie-Mélanie, Delrée, Paul, Devouassoux, Mojgan, Fiche, Maryse, Fondrevelle, Marie-Eve, Fridman, Viviana, Garbar, Christian, Genin, Pascal, Ghnassia, Jean-Pierre, Haudebourg, Juliette, Laberge-Le Couteulx, Sophie, Loussouarn, Delphine, Maran-Gonzalez, Aurélie, Marcy, Myriam, Michenet, Patrick, Poulet, Bruno, Sagan, Christine, Trassard, Martine, Verriele, Véronique, Arnould, Laurent, and Lacroix-Triki, Magali

Published
2014
Full Text
View/download PDF

12. Recommandations du GEFPICS concernant la phase pré-analytique pour l’évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour 2014

Author

MacGrogan, Gaëtan, Mathieu, Marie-Christine, Poulet, Bruno, Penault-Llorca, Frédérique, Vincent-Salomon, Anne, Roger, Pascal, Treilleux, Isabelle, Valent, Alexander, Antoine, Martine, Becette, Véronique, Bor, Catherine, Brabencova, Eva, Charafe-Jauffret, Emmanuelle, Chenard, Marie-Pierre, Dauplat, Marie-Mélanie, Delrée, Paul, Devouassoux, Mojgan, Fiche, Maryse, Fondrevelle, Marie-Eve, Fridman, Viviana, Garbar, Christian, Genin, Pascal, Ghnassia, Jean-Pierre, Haudebourg, Juliette, Laberge-Le Couteulx, Sophie, Loussouarn, Delphine, Maran-Gonzalez, Aurélie, Marcy, Myriam, Michenet, Patrick, Sagan, Christine, Trassard, Martine, Verriele, Véronique, Arnould, Laurent, and Lacroix-Triki, Magali

Published
2014
Full Text
View/download PDF

13. A catalog of numerical centrosome defects in epithelial ovarian cancers

Author

Morretton, Jean‐Philippe, primary, Simon, Anthony, additional, Herbette, Aurélie, additional, Barbazan, Jorge, additional, Pérez‐González, Carlos, additional, Cosson, Camille, additional, Mboup, Bassirou, additional, Latouche, Aurélien, additional, Popova, Tatiana, additional, Kieffer, Yann, additional, Macé, Anne‐Sophie, additional, Gestraud, Pierre, additional, Bataillon, Guillaume, additional, Becette, Véronique, additional, Meseure, Didier, additional, Nicolas, André, additional, Mariani, Odette, additional, Vincent‐Salomon, Anne, additional, Stern, Marc‐Henri, additional, Mechta‐Grigoriou, Fatima, additional, Roman Roman, Sergio, additional, Vignjevic, Danijela Matic, additional, Rouzier, Roman, additional, Sastre‐Garau, Xavier, additional, Goundiam, Oumou, additional, and Basto, Renata, additional

Published
2022
Full Text
View/download PDF

14. APC germline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?

Author

Vibert, Roseline, Le Gall, Jessica, Buecher, Bruno, Mouret-Fourme, Emmanuelle, Bataillon, Guillaume, Becette, Véronique, Trabelsi-Grati, Olfa, Moncoutier, Virginie, Dehainault, Catherine, Carriere, Jennifer, Schwartz, Mathias, Suybeng, Voreak, Bieche, Ivan, Colas, Chrystelle, Vincent-Salomon, Anne, Stoppa-Lyonnet, Dominique, and Golmard, Lisa

Abstract

APC germline pathogenic variants result in predisposition to familial adenomatous polyposis and extraintestinal tumours such as desmoid fibromatosis, medulloblastomas and thyroid cancers. They have also been recently involved in ovarian microcystic stromal tumours. APC inactivation has been described at the tumour level in epithelial ovarian cancers (EOCs). Here, we report the identification of APC germline pathogenic variants in two patients diagnosed with premenopausal EOC in early 30s, with no other pathogenic variant detected in the known ovarian cancer predisposing genes. Subsequent tumour analysis showed neither a second hit of APC inactivation nor β-catenin activation. Both tumours did not have a homologous recombination (HR) deficiency, pointing towards the implication of other genes than those involved in HR. APC may contribute to the carcinogenesis of EOC in a multifactorial context. Further studies are required to clarify the role of APC in predisposition to EOC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Centrosome amplification favours survival and impairs ovarian cancer progression

Author

Morretton, Jean-Philippe, Herbette, Aurélie, Cosson, Camille, Mboup, Bassirou, Latouche, Aurélien, Gestraud, Pierre, Popova, Tatiana, Stern, Marc-Henri, Nemati, Fariba, Decaudin, Didier, Bataillon, Guillaume, Becette, Véronique, Meseure, Didier, Nicolas, André, Mariani, Odette, Bonneau, Claire, Barbazan, Jorge, Vincent-Salomon, Anne, Mechta-Grigoriou, Fatima, Roman, Sergio Roman, Rouzier, Roman, Sastre-Garau, Xavier, Goundiam, Oumou, Basto, Renata, Centre de recherche de l'Institut Curie [Paris], and Institut Curie [Paris]

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Centrosome amplification has been described as a common feature of human cancers and it is known to promote tumorigenesis when induced in animals. However, little is known about the real status of centrosome numbers in human cancers and whether numerical alterations are solely associated with poor prognosis. To address this question, we have analyzed a large cohort of human epithelial ovarian cancers (EOCs) from 100 patients using state-of-the-art microscopy to determine the Centrosome-Nucleus Index (CNI) of each tumor. We found that EOCs are highly heterogeneous, with infrequent but strong centrosome amplifications leading to higher CNI than in healthy tissues. Strikingly, while a correlation between CNI and genomic alterations, such as aneuploidy or chromosome rearrangements could not be established, we found that high CNI correlates with increased patient survival and sensitivity to chemotherapy. Using ovarian cancer cellular models to manipulate centrosome numbers and Patient-Derived Xenografts (PDXs), we found that higher CNIs can positively impact the response to chemotherapy and inhibit cell dissemination. Our findings highlight a novel paradigm linking centrosome amplification to the inhibition of tumor progression.

Published
2021

16. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Author

Bonnefoi, Hervé, Piccart, Martine, Bogaerts, Jan, Mauriac, Louis, Fumoleau, Pierre, Brain, Etienne, Petit, Thierry, Rouanet, Philippe, Jassem, Jacek, Blot, Emmanuel, Zaman, Khalil, Cufer, Tanja, Lortholary, Alain, Lidbrink, Elisabet, André, Sylvie, Litière, Saskia, Lago, Lissandra Dal, Becette, Véronique, Cameron, David A, Bergh, Jonas, and Iggo, Richard

Published
2011
Full Text
View/download PDF

19. APCgermline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?

Author

Vibert, Roseline, Le Gall, Jessica, Buecher, Bruno, Mouret-Fourme, Emmanuelle, Bataillon, Guillaume, Becette, Véronique, Trabelsi-Grati, Olfa, Moncoutier, Virginie, Dehainault, Catherine, Carriere, Jennifer, Schwartz, Mathias, Suybeng, Voreak, Bieche, Ivan, Colas, Chrystelle, Vincent-Salomon, Anne, Stoppa-Lyonnet, Dominique, and Golmard, Lisa

Abstract

APCgermline pathogenic variants result in predisposition to familial adenomatous polyposis and extraintestinal tumours such as desmoid fibromatosis, medulloblastomas and thyroid cancers. They have also been recently involved in ovarian microcystic stromal tumours. APCinactivation has been described at the tumour level in epithelial ovarian cancers (EOCs). Here, we report the identification of APCgermline pathogenic variants in two patients diagnosed with premenopausal EOC in early 30s, with no other pathogenic variant detected in the known ovarian cancer predisposing genes. Subsequent tumour analysis showed neither a second hit of APCinactivation nor β-catenin activation. Both tumours did not have a homologous recombination (HR) deficiency, pointing towards the implication of other genes than those involved in HR. APCmay contribute to the carcinogenesis of EOC in a multifactorial context. Further studies are required to clarify the role of APCin predisposition to EOC.

Published
2023
Full Text
View/download PDF

20. Adaptive nanopore sequencing to determine pathogenicity of BRCA1exonic duplication

Author

Filser, Mathilde, Schwartz, Mathias, Merchadou, Kevin, Hamza, Abderaouf, Villy, Marie-Charlotte, Decees, Antoine, Frouin, Eléonore, Girard, Elodie, Caputo, Sandrine M, Renault, Victor, Becette, Véronique, Golmard, Lisa, Servant, Nicolas, Stoppa-Lyonnet, Dominique, Delattre, Olivier, Colas, Chrystelle, and Masliah-Planchon, Julien

Abstract

BRCA1and BRCA2are tumour suppressor genes that have been characterised as predisposition genes for the development of hereditary breast and ovarian cancers among other malignancies. The molecular diagnosis of this predisposition syndrome is based on the detection of inactivating variants of any type in those genes. But in the case of structural variants, functional consequences can be difficult to assess using standard molecular methods, as the precise resolution of their sequence is often impossible with short-read next generation sequencing techniques. It has been recently demonstrated that Oxford Nanopore long-read sequencing technology can accurately and rapidly provide genetic diagnoses of Mendelian diseases, including those linked to pathogenic structural variants. Here, we report the accurate resolution of a germline duplication event of exons 18–20 of BRCA1using Nanopore sequencing with adaptive sampling target enrichment. This allowed us to classify this variant as pathogenic within a short timeframe of 10 days. This study provides a proof-of-concept that nanopore adaptive sampling is a highly efficient technique for the investigation of structural variants of tumour suppressor genes in a clinical context.

Published
2023
Full Text
View/download PDF

23. Co-occurrence of germline BRCA1 and CDH1 pathogenic variants

Author

Villy, Marie-Charlotte, primary, Mouret-Fourme, Emmanuelle, additional, Golmard, Lisa, additional, Becette, Véronique, additional, Callet, Nasrine, additional, Marx, Gilles, additional, Colas, Chrystelle, additional, Lamarque, Dominique, additional, Rouleau, Etienne, additional, and Stoppa-Lyonnet, Dominique, additional

Published
2020
Full Text
View/download PDF

25. Co-occurrence of germline BRCA1 and CDH1 pathogenic variants.

Author

Villy, Marie-Charlotte, Mouret-Fourme, Emmanuelle, Golmard, Lisa, Becette, Véronique, Callet, Nasrine, Marx, Gilles, Colas, Chrystelle, Lamarque, Dominique, Rouleau, Etienne, and Stoppa-Lyonnet, Dominique

Abstract

Introduction: We report a very rare case of familial breast cancer and diffuse gastric cancer, with germline pathogenic variants in both BRCA1 and CDH1 genes. To the best of our knowledge, this is the first report of such an association. Family description: The proband is a woman diagnosed with breast cancer at the age of 52 years. She requested genetic counselling in 2012, at the age of 91 years, because of a history of breast cancer in her daughter, her sister, her niece and her paternal grandmother and was therefore concerned about her relatives. Her sister and maternal aunt also had gastric cancer. She was tested for several genes associated with hereditary breast cancer. Results: A large deletion of BRCA1 from exons 1 to 7 and two CDH1 pathogenic cis variants were identified. Conclusion: This complex situation is challenging for genetic counselling and management of at-risk individuals. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers

Author

Tury, Sandrine, Assayag, Franck, Bonin, Florian, Chateau-Joubert, Sophie, Servely, Jean Luc, Vacher, Sophie, Becette, Véronique, Caly, Martial, Rapinat, Audrey, Gentien, David, De La Grange, Pierre, Schnitzler, Anne, Lallemand, François, Marangoni, Elisabetta, Bièche, Ivan, Callens, Céline, Institut Curie [Paris], BioPôle Alfort, École nationale vétérinaire d'Alfort (ENVA), Biologie du Développement et Reproduction (BDR), École nationale vétérinaire d'Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA), Hôpital René HUGUENIN (Saint-Cloud), Department of Biopathology, Università degli Studi di Roma Tor Vergata [Roma], GenoSplice, Ltd, Génétique, physiopathologie et approches thérapeutiques des maladies héréditaires du système nerveux (EA 7331), Université Paris Descartes - Paris 5 (UPD5), Fondation ARC pour la recherche sur le cancer, 20141201685, and Fondation de France, 201400047492

Subjects
Time Factors, [SDV]Life Sciences [q-bio], Iron, Mice, Nude, Apoptosis, Triple Negative Breast Neoplasms, Adenocarcinoma, chemotherapy, Iron Chelating Agents, Carboplatin, breast cancer, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Animals, Humans, iron metabolism, [INFO]Computer Science [cs], Cell Proliferation, NF-kappa B, Drug Synergism, Xenograft Model Antitumor Assays, Deferasirox, Doxorubicin, MCF-7 Cells, iron chelators, Cisplatin, Phosphatidylinositol 3-Kinase, Signal Transduction
Abstract

To ensure their high proliferation rate, tumor cells have an iron metabolic disorder causing them to have increased iron needs, making them more susceptible to iron deprivation. This vulnerability could be a therapeutic target. In breast cancers, the development of new therapeutic approaches is urgently needed for patients with triple-negative tumors, which frequently relapse after chemotherapy and suffer from a lack of targeted therapies. In this study, we demonstrated that deferasirox (DFX) synergises with standard chemotherapeutic agents such as doxorubicin, cisplatin and carboplatin to inhibit cell proliferation and induce apoptosis and autophagy in triple-negative breast cancer (TNBC) cells. Moreover, the combination of DFX with doxorubicin and cyclophosphamide delayed recurrences in breast cancer patient-derived xenografts without increasing the side-effects of chemotherapies alone or altering the global iron storage of mice. Antitumor synergy of DFX and doxorubicin seems to involve downregulation of the phosphoinositide 3-kinase and nuclear factor-κB pathways. Iron deprivation in combination with chemotherapy could thus help to improve the effectiveness of chemotherapy in TNBC patients without increasing toxicity. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John WileySons, Ltd.

Published
2018

27. Additional file 3: of Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Author

Liang, Xu, Briaux, Adrien, Becette, Véronique, Benoist, Camille, Anais Boulai, Chemlali, Walid, Schnitzler, Anne, Baulande, Sylvain, Rivera, Sofia, Marie-Ange Mouret-Reynier, Bouvet, Laurence, Rouge, Thibaut De La Motte, Lemonnier, Jérôme, Lerebours, Florence, and Callens, Céline

Abstract

Figure S2. Number of overlapping DEGs on pre- and post-NET in responders defined by three different response assessments. Venn diagram showing the total numbers and overlapping numbers of differentially expressed genes pre-NET compared to post-NET based on RNA sequencing data for responding patients using three different evaluation methods. DEGs: differentially expressed genes. (PDF 15 kb)

Published
2018
Full Text
View/download PDF

28. Low centrosome numbers correlate with higher aggressivity in ovarian cancer

Author

Morretton, Jean-Philippe, primary, Simon, Anthony, additional, Herbette, Aurélie, additional, Barbazan, Jorge, additional, Pérez-González, Carlos, additional, Cosson, Camille, additional, Mboup, Bassirou, additional, Latouche, Aurélien, additional, Popova, Tatiana, additional, Kieffer, Yann, additional, Gestraud, Pierre, additional, Bataillon, Guillaume, additional, Becette, Véronique, additional, Meseure, Didier, additional, Nicolas, André, additional, Mariani, Odette, additional, Vincent-Salomon, Anne, additional, Stern, Marc-Henri, additional, Mechta-Grigoriou, Fatima, additional, Roman, Sergio Roman, additional, Vignjevic, Danijela Matic, additional, Rouzier, Roman, additional, Sastre-Garau, Xavier, additional, Goundiam, Oumou, additional, and Basto, Renata, additional

Published
2019
Full Text
View/download PDF

30. Co-occurrence of germline BRCA1and CDH1pathogenic variants

Author

Villy, Marie-Charlotte, Mouret-Fourme, Emmanuelle, Golmard, Lisa, Becette, Véronique, Callet, Nasrine, Marx, Gilles, Colas, Chrystelle, Lamarque, Dominique, Rouleau, Etienne, and Stoppa-Lyonnet, Dominique

Abstract

Introduction: We report a very rare case of familial breast cancer and diffuse gastric cancer, with germline pathogenic variants in both BRCA1and CDH1genes. To the best of our knowledge, this is the first report of such an association.Family description: The proband is a woman diagnosed with breast cancer at the age of 52 years. She requested genetic counselling in 2012, at the age of 91 years, because of a history of breast cancer in her daughter, her sister, her niece and her paternal grandmother and was therefore concerned about her relatives. Her sister and maternal aunt also had gastric cancer. She was tested for several genes associated with hereditary breast cancer.Results: A large deletion of BRCA1from exons 1 to 7 and two CDH1pathogenic cisvariants were identified.Conclusion: This complex situation is challenging for genetic counselling and management of at-risk individuals.

Published
2021
Full Text
View/download PDF

34. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus‐associated invasive carcinoma

Author

Jeannot, Emmanuelle, primary, Becette, Véronique, additional, Campitelli, Maura, additional, Calméjane, Marie‐Ange, additional, Lappartient, Emmanuelle, additional, Ruff, Evelyne, additional, Saada, Stéphanie, additional, Holmes, Allyson, additional, Bellet, Dominique, additional, and Sastre‐Garau, Xavier, additional

Published
2016
Full Text
View/download PDF

37. Histo-genomic stratification reveals the frequent amplification/overexpression ofCCNE1andBRD4genes in non-BRCAness high grade ovarian carcinoma

Author

Goundiam, Oumou, primary, Gestraud, Pierre, additional, Popova, Tatiana, additional, De la Motte Rouge, Thibault, additional, Fourchotte, Virginie, additional, Gentien, David, additional, Hupé, Philippe, additional, Becette, Véronique, additional, Houdayer, Claude, additional, Roman-Roman, Sergio, additional, Stern, Marc-Henri, additional, and Sastre-Garau, Xavier, additional

Published
2015
Full Text
View/download PDF

38. Quiz case. Breast sarcoidosis presenting as a metastatic breast cancer

Author

El Khoury, Mona, Cherel, Pascal, Hagay, Charley, Bertrand, Françoise, Becette, Véronique, and Plantet, Marie-Madeleine

Subjects
Diagnosis, Differential, Diagnostic Imaging, Breast Diseases, Sarcoidosis, Humans, Breast Neoplasms, Female, Middle Aged
Abstract

A case of sarcoidosis presenting initially as a breast mass with subclinical pulmonary and medullary involvement highly mimicking metastatic breast carcinoma is reported. The mammographic, ultrasound and CT scan findings are described with a review of the literature.

Published
2004

40. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE 1 and BRD 4 genes in non-BRCAness high grade ovarian carcinoma.

Author

Goundiam, Oumou, Gestraud, Pierre, Popova, Tatiana, De la Motte Rouge, Thibault, Fourchotte, Virginie, Gentien, David, Hupé, Philippe, Becette, Véronique, Houdayer, Claude, Roman‐Roman, Sergio, Stern, Marc‐Henri, and Sastre‐Garau, Xavier

Abstract

The treatment of epithelial ovarian cancer (EOC) is narrowly focused despite the heterogeneity of this disease in which outcomes remain poor. To stratify EOC patients for targeted therapy, we developed an approach integrating expression and genomic analyses including the BRCAness status. Gene expression and genomic profiling were used to identify genes recurrently (>5%) amplified and overexpressed in 105 EOC. The LST (Large-scale State Transition) genomic signature of BRCAness was applied to define molecular subgroups of EOC. Amplified/overexpressed genes clustered mainly in 3q, 8q, 19p and 19q. These changes were generally found mutually exclusive. In the 85 patients for which the genomic signature could be determined, genomic BRCAness was found in 52 cases (61.1%) and non-BRCAness in 33 (38.8%). A striking mutual exclusivity was observed between BRCAness and amplification/overexpression data. Whereas 3q and 8q alterations were preferentially observed in BRCAness EOC, most alterations on chromosome 19 were in non-BRCAness cases. CCNE1 (19q12) and BRD4 (19p13.1) amplification/overexpression was found in 19/33 (57.5%) of non-BRCAness cases. Such disequilibrium was also found in the TCGA EOC data set used for validation. Potential target genes are frequently amplified/overexpressed in non-BRCAness EOC. We report that BRD4, already identified as a target in several tumor models, is a new potential target in high grade non-BRCAness ovarian carcinoma. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

42. Retraction—validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

Author

Bonnefoi, Hervé, primary, Potti, Anil, additional, Delorenzi, Mauro, additional, Mauriac, Louis, additional, Campone, Mario, additional, Tubiana-Hulin, Michèle, additional, Petit, Thierry, additional, Rouanet, Philippe, additional, Jassem, Jacek, additional, Blot, Emmanuel, additional, Becette, Véronique, additional, Farmer, Pierre, additional, André, Sylvie, additional, Acharya, Chaitanya R, additional, Mukherjee, Sayan, additional, Cameron, David, additional, Bergh, Jonas, additional, Nevins, Joseph R, additional, and Iggo, Richard D, additional

Published
2011
Full Text
View/download PDF

43. RETRACTED: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

Author

Bonnefoi, Hervé, Potti, Anil, Delorenzi, Mauro, Mauriac, Louis, Campone, Mario, Tubiana-Hulin, Michèle, Petit, Thierry, Rouanet, Philippe, Jassem, Jacek, Blot, Emmanuel, Becette, Véronique, Farmer, Pierre, André, Sylvie, Acharya, Chaitanya R, Mukherjee, Sayan, Cameron, David, Bergh, Jonas, Nevins, Joseph R, and Iggo, Richard D

Published
2007
Full Text
View/download PDF

44. Erratum: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Author

Farmer, Pierre, primary, Bonnefoi, Hervé, additional, Anderle, Pascale, additional, Cameron, David, additional, Wirapati, Pratyaksha, additional, Becette, Véronique, additional, André, Sylvie, additional, Piccart, Martine, additional, Campone, Mario, additional, Brain, Etienne, additional, MacGrogan, Gaëtan, additional, Petit, Thierry, additional, Jassem, Jacek, additional, Bibeau, Frédéric, additional, Blot, Emmanuel, additional, Bogaerts, Jan, additional, Aguet, Michel, additional, Bergh, Jonas, additional, Iggo, Richard, additional, and Delorenzi, Mauro, additional

Published
2009
Full Text
View/download PDF

45. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Author

Farmer, Pierre, primary, Bonnefoi, Hervé, additional, Anderle, Pascale, additional, Cameron, David, additional, Wirapati, Pratyakasha, additional, Becette, Véronique, additional, André, Sylvie, additional, Piccart, Martine, additional, Campone, Mario, additional, Brain, Etienne, additional, MacGrogan, Gaëtan, additional, Petit, Thierry, additional, Jassem, Jacek, additional, Bibeau, Frédéric, additional, Blot, Emmanuel, additional, Bogaerts, Jan, additional, Aguet, Michel, additional, Bergh, Jonas, additional, Iggo, Richard, additional, and Delorenzi, Mauro, additional

Published
2009
Full Text
View/download PDF

48. Prognostic Value of MIB–1 Antibody Labeling Index to Predict Response to Bacillus Calmette–Guérin Therapy in a High–Risk Selected Population of Patients with Stage T1 Grade G3 Bladder Cancer

Author

Lebret, Thierry, primary, Becette, Véronique, additional, Hervé, Jean-Marie, additional, Molinié, Vincent, additional, Barré, Philippe, additional, Lugagne, Pierre-Marie, additional, Gentille, Annie, additional, Baglin, Anne-Catherine, additional, and Botto, Henry, additional

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results